Oncologists vary widely in treating DLBCL with cardiomyopathy, often diverging from guidelines due to limited evidence on ...

When tested in a mouse model of breast cancer, the doxorubicin-loaded nanoparticles caused fewer side effects than free ...

Beerse: Janssen-Cilag International NV, a Johnson & Johnson company, has announced that the Committee for Medicinal Products ...

Scientists at Xi'an Jiaotong-Liverpool University (XJTLU) and Nanjing University in China have developed a new drug delivery ...

Scientists at Xi'an Jiaotong-Liverpool University (XJTLU) and Nanjing University in China have developed a new drug delivery ...

A Peter Mac-initiated clinical trial suggests a way to dramatically improve outcomes in patients with high-risk forms of ...

Cancer statistics are equally grim. The Kenya National Cancer Registry estimates 42,000 new cancer cases and 27,000 deaths ...

Scientists at Xi'an Jiaotong-Liverpool University (XJTLU) and Nanjing University in China have developed a new drug delivery system that could ...

Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than R-GemOx 1 This well-tolerated investigational combination therapy avoids traditional ...

Eighty-five percent of the 720 cycles were delivered on schedule at full dose, and the median RDI of the cyclophosphamide and doxorubicin ... %. Of the 110 cycles of chemotherapy administered ...